|Thread||Thread Starter||Forum||Replies||Last Post|
|AGBT 2013 posters||swarner||Events / Conferences||0||02-26-2013 10:09 AM|
|Agbt 2013||paulk||Events / Conferences||0||02-16-2013 07:01 AM|
|'Spring School 2013 - Epigenetics of Civilization Diseases', May 27th - 31st 2013||ecSeq Bioinformatics||Events / Conferences||1||01-31-2013 01:17 PM|
|Have a great 2013!||EricP||Introductions||0||01-09-2013 02:03 AM|
|05-30-2013, 11:56 AM||#1|
Join Date: Mar 2013
Day 1 highlights of Sequencing, Finishing and Analysis in the Future Meeting (SFAF 2013)
• All four platforms are actively trying to increase their read lengths (although we didn’t see significant guidance beyond Ion’s 400 bp reads)
• Haley mentioned that Illumina’s latest aquisition of Moleculo technology might one day replace current Mate-pair library prep (if prices can be lowered).
• MiSeq DX was pulled back because Illumina has been able to increase MiSeq output. A clinical instrument will require a locked down platform.
• Turner said that he expects 30,000 PacBio base pairs in 3 years. Shearing technologies and polymerases would have to be improved for better-read lengths.
• PGM can produce >2G aligned Q20 bases with even coverage (E. coli) using their 318, 400 bp chip.
• Fiske said that Illumina spends 25% of revenue on R&D, Life Tech and Thermo spend 5% and 3% respectively.
• Illumina needs help with better and higher fidelity polymerases. Suggested that Illumina would consider purchasing companies who have breakthrough technologies related to polymerases.
SFAF day 1 summary
Last edited by Genohub; 07-29-2013 at 02:16 PM. Reason: link update
|sfaf, sfaf 2013|